Zurcher Kantonalbank Zurich Cantonalbank Boosts Stake in Evolent Health, Inc. (NYSE:EVH)

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Evolent Health, Inc. (NYSE:EVH) by 12.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,355 shares of the technology company’s stock after acquiring an additional 2,677 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Evolent Health were worth $771,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Bank of New York Mellon Corp grew its stake in shares of Evolent Health by 8.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,655,609 shares of the technology company’s stock valued at $45,082,000 after purchasing an additional 133,038 shares during the period. Brown Advisory Inc. raised its position in shares of Evolent Health by 17.8% during the third quarter. Brown Advisory Inc. now owns 36,870 shares of the technology company’s stock valued at $1,004,000 after buying an additional 5,564 shares during the last quarter. Summit Creek Advisors LLC increased its holdings in Evolent Health by 0.4% in the 3rd quarter. Summit Creek Advisors LLC now owns 559,495 shares of the technology company’s stock valued at $15,235,000 after acquiring an additional 2,425 shares during the last quarter. Teacher Retirement System of Texas lifted its position in shares of Evolent Health by 9.0% in the third quarter. Teacher Retirement System of Texas now owns 8,293 shares of the technology company’s stock worth $226,000 after buying an additional 685 shares in the last quarter. Finally, Zevenbergen Capital Investments LLC raised its holdings in shares of Evolent Health by 25.4% during the 3rd quarter. Zevenbergen Capital Investments LLC now owns 17,750 shares of the technology company’s stock worth $483,000 after acquiring an additional 3,600 shares in the last quarter.

Evolent Health Stock Performance

NYSE:EVH opened at $27.82 on Tuesday. Evolent Health, Inc. has a 12 month low of $23.33 and a 12 month high of $36.70. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.01 and a quick ratio of 1.01. The firm has a market capitalization of $3.21 billion, a PE ratio of -21.91 and a beta of 1.54. The business’s fifty day moving average price is $31.71 and its 200 day moving average price is $30.29.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, February 22nd. The technology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.13. Evolent Health had a positive return on equity of 6.60% and a negative net margin of 5.76%. The business had revenue of $556.06 million for the quarter, compared to the consensus estimate of $541.87 million. On average, sell-side analysts anticipate that Evolent Health, Inc. will post 0.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on the company. William Blair reaffirmed an “outperform” rating on shares of Evolent Health in a research report on Tuesday, January 9th. Canaccord Genuity Group decreased their price target on Evolent Health from $45.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, March 28th. Barclays started coverage on shares of Evolent Health in a report on Wednesday, January 3rd. They set an “overweight” rating and a $39.00 price objective on the stock. Citigroup started coverage on shares of Evolent Health in a report on Monday, April 22nd. They issued a “buy” rating and a $40.00 price target on the stock. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Evolent Health from $53.00 to $52.00 and set an “overweight” rating for the company in a research report on Friday, March 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, Evolent Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.70.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.